The U.S. Food and Drug Administration has cleared Astellas Pharma (TYO:4503) and Pfizer's bladder cancer drug combination, PADCEV and Keytruda, according to a joint release on Friday.
The FDA cleared the combo for adults with severe bladder cancer to use before and after surgery.
This broadens a prior November 2025 approval that limited the drug's use to cisplatin-ineligible patients with muscle-invasive bladder cancer.
Guangzhou Automobile Group or GAC (HKG:2238, SHA:601238) expects an attributable loss of between 4.06 billion yuan and 4.57 billion yuan for the first half of 2026, wider than 2.54 billion yuan a year prior.The automaker attributed the forecast to a wider loss from self-developed brands, lower investment income, and foreign exchange losses, according to a Friday Hong Kong bourse filing.
Jiumaojiu International Holdings (HKG:9922) posted mixed results for same-store average daily sales across major brands in the second quarter of 2026, according to a Friday Hong Kong bourse filing.Self-operated Tai Er stores recorded a 6.1% rise in same-store average daily sales. On the other hand, Song Hot Pot fell 26% and Jiu Mao Jiu declined 14%.As of June 30, Jiumaojiu operated 606 restaurants, including 477 Tai Er outlets.Average spending per customer across major brands has remained relatively stable for several consecutive quarters.
CSSC Offshore & Marine Engineering (HKG:0317, SHA:600685) expects an attributable profit of between 790 million yuan and 890 million yuan for the first half of 2026, up 50% to 69% from 526.4 million yuan a year prior.The marine and defense equipment manufacturer attributed the forecast to a rise in product gross profit amid production and operational efficiency, as well as higher recognized investment income.